Zacks: Brokerages Anticipate Novavax, Inc. (NVAX) to Announce -$0.15 Earnings Per Share
Wall Street brokerages expect Novavax, Inc. (NASDAQ:NVAX) to report ($0.15) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Novavax’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.14). Novavax posted earnings of ($0.21) per share in the same quarter last year, which would indicate a positive year over year growth rate of 28.6%. The business is scheduled to announce its next quarterly earnings results on Monday, February 26th.
According to Zacks, analysts expect that Novavax will report full-year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.65) to ($0.60). For the next year, analysts anticipate that the business will report earnings of ($0.60) per share, with EPS estimates ranging from ($0.83) to ($0.50). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Novavax.
Several research firms recently commented on NVAX. B. Riley set a $10.00 price objective on Novavax and gave the company a “buy” rating in a research note on Thursday, January 11th. Ladenburg Thalmann Financial Services increased their price objective on Novavax to $2.50 and gave the company a “buy” rating in a research note on Thursday, January 11th. S&P Equity Research reduced their price objective on Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price objective on shares of Novavax in a research note on Wednesday, November 8th. Finally, Citigroup downgraded Novavax from a “buy” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research note on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $2.64.
Novavax (NVAX) opened at $2.03 on Thursday. Novavax has a 52 week low of $0.73 and a 52 week high of $2.32. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of -4.28. The company has a market capitalization of $636.64, a price-to-earnings ratio of -2.99 and a beta of 2.68.
TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate Novavax, Inc. (NVAX) to Announce -$0.15 Earnings Per Share” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/02/15/zacks-brokerages-anticipate-novavax-inc-nvax-to-announce-0-15-earnings-per-share.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.